secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001558370-25-003241
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path pre-clinical data shows BP1001-A restores insulin sensitivity, supporting obesity/T2D potential
--------------------------------------------------------------------------------

- BP1001-A attenuated palmitic acid-induced insulin resistance in C2C12 myoblasts and myotubes.
- Final pre-clinical mouse model study expected H1 2025; IND filing planned by year-end.
- BP1001-A downregulates Grb2 expression to increase insulin sensitivity in muscle cells.
- CEO cites need for alternative glucose-lowering treatments in obese T2D patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025003241/0001558370-25-003241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025003241/bpth-20250318x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer